When was Genedit founded?

Genedit was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Genedit located?

Genedit is headquartered in Berkeley, United States. It is registered at 681 Gateway Blvd 3rd Floor South San Francisco, CA, 94080.

How many employees does Genedit have?

As of May 31, 2026, the latest employee count at Genedit is 65.

Is Genedit a funded company?

Genedit is a funded company, having raised a total of $93.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 11, 2018.

When was the latest funding round of Genedit?

Genedit's latest funding was a $***** Series B round on Nov 20, 2024, with participation from 3 investors.

Where does Genedit rank among its competitors?

Genedit ranks 2nd amongst 345 active competitors, of which 104 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was SonoThera, which secured $125M in Jun, 2026.

Who are the top competitors of Genedit?

Genedit's top competitors include Liquidia, Aera and NanoSyrinx. Among them, SonoThera secured the most recent funding round in June, 2026.

Genedit - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drug delivery system for genetic medicines. The company has developed a NanoGalaxy platform that contains non-viral, non-lipid, polymer nanoparticles to deliver genetic medicines to the needed tissue to treat disease.

Website: genedit.com
Social
Email ID: *****@genedit.com
Registered Address: 681 Gateway Blvd 3rd Floor South San Francisco, CA, 94080

Key Metrics

Founded Year

2016

Location

Berkeley, United States

Stage

Series B

Total Funding

$93.5M in 5 rounds

Latest Funding Round

Series B, Nov 20, 2024, $*****

Investors

DCVC & 21 more

Ranked

2^nd among 345 active competitors

Employee Count

65 as on May 31, 2026

Investment & Acquisitions

Auron Therapeutics

Similar Companies

Liquidia & 464 more

View Genedit's full profile

Genedit is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GENEDIT INC CIN: 812419163 , United States, Active	Dec 31, 1999	-	34 (As on Dec 31, 2024)	-

Genedit has raised a total funding of $93.5M over 5 rounds. Its first funding round was on Dec 11, 2018. Its latest funding round was a Series B round on Nov 20, 2024 for $*****. 3 investors participated in its latest round. Genedit has 22 institutional investors.

Here is the list of recent funding rounds of Genedit:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 20, 2024	3420648	Series B	1364719	5326719	7826658	5422165
Jan 23, 2024	6556113	Series A	6064516	3874888	7224955	6563672
Sep 23, 2021	2202419	Series A	6752899	5932335	Lilly & 5 more	Time Polio Asset Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Genedit's funding rounds and investors

The founders of Genedit is Kunwoo Lee.

Here are the details of Genedit's key team members:

Kunwoo Lee: Founder of Genedit.
Contact Info: 1 email address

View details of Genedit's Founder profiles and Board Members

Genedit's employee count trend

Genedit has 65 employees as of May 26. Here is Genedit's employee count trend over the years:

Uncover Genedit's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genedit include Liquidia, Aera and NanoSyrinx. Here is the list of Top 10 competitors of Genedit, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
2nd	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	SK, Lilly & 20 others	65/100
3rd	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Arch Venture Partners, Google Ventures & 3 others	62/100
4th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Octopus Ventures, M Ventures & 15 others	61/100
5th	Portal 2023, Watertown (United States), Seed	Provider of cell engineering and cell analytics across research and clinical applications	$25.7M	NFX, IA Ventures & 7 others	61/100
6th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100
7th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 4 others	59/100
8th	SonoThera 2022, San Francisco (United States), Series B	Developer of nonviral gene therapies for genetic diseases	$186M	Arch Venture Partners, Vida Ventures & 21 others	57/100
9th	YolTech 2021, Shanghai (China), Series C	Developer of gene editing and LNP delivery platforms for therapeutics	$133M	Decheng Capital, Loayal Valley Capital & 10 others	57/100
10th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	57/100